Par Pharmaceutical Cos Inc

Deals

CCYSZE(M)TNRMTYRNKMOSPFITYPEBNCHIPTGDNCSPRDCPNNICPRICE
USD1,500.0008Apr-27Sr. SecuredBa3B+-FixedTsy--4937.50%-100.00000
Tranche Comments
8 yr: First Pay: 2019-10-01; Registration: 144A/Reg S; Comments: Up to USD1.5bn from (USD1bn) 8yr 7.500% Fxd. snr sec 144A/RegS for life. Ba3/B+. JPM/Citi/Barc/BAML/CS/DB/GS/MS/RBC. T+493bp Mixed Call sched: 2022 at 105.625%, 2023 at 103.750%, 2024 at 101.875%, 2025 at par. MWC+50bp. Equity claw: 35% prior to 4/1/22 at 107.500%. CoC: 101%. (Source: IFR);
Use of Proceeds
General corporate purposes

B&I

BWICS & Inventory

This module is available on the Professional plan. Learn moreUpgrade Plan

TRACE

This module is available on the Professional plan. Learn moreUpgrade Plan

Research